Clinical guidelines endorse GLP-1 RA as the primary glucose-lowering agents for treating T2DM patients with concurrent atherosclerotic cardiovascular disease and as a secondary option for DKD treatment (1, 22). This evidence concerns the gene GCG and diabetic kidney disease.